New 1,2,4-thiadiazolylnitrones and furoxanylnitrones were developed and evaluated as neuroprotective agents on a human neuroblastoma (SH-SY5Y) cells model. They inhibited at low micromolar concentrations the oxidative damage and the death induced by exposure to hydrogen peroxide. These heteroarylnitrones showed excellent peroxyl free radical absorbance capacities, analyzed by oxygen radical absorbance capacity (ORAC) assay with fluorescein as the fluorescent probe, ranging from 1.5-to 16.5-fold the value of the reference nitrone, R-phenyl-N-tert-butylnitrone (PBN). The electron spin resonance spectroscopy (ESR) demonstrated the ability of these derivatives to directly trap and stabilize oxygen, carbon, and sulfur-centered free radicals. These results demonstrated the potential use of these heteroarylnitrones as neuroprotective agents in preventing the death of cells exposed to enhanced oxidative stress and damage.
Introduction
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) produced by oxidative metabolism are capable of damaging cellular components through molecular modifications to a polyunsaturated membrane's lipids, proteins, and nucleic acids. 1, 2 Much evidence suggests that biological oxidation in the human body generates highly pathogenic ROS and RNS such as hydroxyl free radical (
• OH), superoxide anion (O 2 •-), peroxynitrite (ONOO -), and lipid peroxide free radicals (ROO • ), causing cellular injury. [3] [4] [5] These pathological events have important roles in many degenerative disorders, for example, atherosclerosis, rheumatoid arthritis, and several neurodegenerative diseases such as ischemic conditions, stroke, Parkinson's disease, and Alzheimer's disease. [6] [7] [8] The central nervous system (CNS) is especially sensitive to oxidative damage for reasons such as (a) high use of oxygen during the metabolic process and therefore greater production of ROS, (b) fewer antioxidants defenses than other organs, for example, liver and heart, (c) enrichment in the more easily peroxidable fatty acids, (d) areas with high levels of the Fe 3+ /ascorbate pro-oxidant system that reduce H 2 O 2 to form
• OH, a potent oxidant. 9 Recently, it has been reported that -amyloid solutions liberate hydrogen peroxide and, subsequently,
• OH converted via Fenton's reaction. 10 Consequently, the search of effective treatments that prevent oxidative stress associated with premature aging and neurodegenerative diseases is an important area of neurochemical research.
Recently, it has been proved that nitrone-free radical trap, i.e., R-phenyl-N-tert-butylnitrone (PBN, a Figure 1 ), could be used in the treatment of neurodegenerative diseases as well as in the prolongation of life span. 11 Initially, the neuroprotective activity was attributed to the nitrone group because of its ability to act as free radical scavenger (FRS, Figure 1 ). Subsequently, observations that PBN has a good neuroprotective activity at lower doses than those necessary to act as an effective FRS demonstrated the ability of PBN to inhibit signal transduction processes such as suppression of proinflammatory cytokines, genes, and mediators associated with enhanced neuroinflammatory processes (Figure 1 ). 12 The neuroprotective activity of the nitrone pharmacophore depends in great part on the connectivity and the nature of substituents on the nitrone group. In this sense, the chemical and pharmacological aspects of different heteroarylnitrones have been reviewed, 13 describing some patented nitrone containing furans (I-III, Figure 2 ) with good activity against the neuronal cell damage induced by -amyloid. 14 On the other hand, imidazolylnitrones (IV and V, Figure 2 ) has been developed and biologically evaluated, showing in vivo neuroprotective properties. 15 Additionally several nitrones has been widely used as spin trap for the specific detection of transient radicals (e.g.,
• OH, O 2 •-, ROO • ) or relatively stable radicals (e.g., NO) that are undetectable under normal conditions, 16 in the electron spin resonance (ESR) spectroscopy. With this aim two nitrones have been commonly used in the spin trapping technique: the linear nitrone PBN (Figure 1 ) and the cyclic nitrone DMPO (5,5-dimethyl-1-pyrroline N-oxide VI, Figure 2 ).
On the basis of that, herein we describe the design and synthesis of new heteroarylnitrones combining, in their structures, fragments able to show neuroprotection properties, such as nitrone moiety, antioxidant fragments, and heterocyclic groups able to stabilize the generated free radical (Scheme 1). In order to assess the protective effects of heteroarylnitrones, the effects of H 2 O 2 -injured in neuronal cells (SH-SY5Y) and in vitro unspecific cytotoxicity against J774-mouse macrophages were evaluated. Additionally, the antioxidant activities and the spin trapping properties have been investigated by evaluating the direct reaction with oxygen-, carbon-, and sulfur-centered free radicals by antioxidant assays and ESR spectroscopy.
Results and Discussion
Chemistry. Four different families of heteroarylnitrones were selected to study the influence on the biological activity: 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-oxadiazole N-oxide, and benzo[1,2-c]1,2,5-oxadiazole N-oxide derivatives. 17, 18 The nitrones syntheses were planned through the condensation between the corresponding heteroaromatic aldehyde and N-substituted hydroxylamine, 19 our first goal being the preparation of the corresponding aldehyde derivatives. For the synthesis of 3-and 5-formyl-1,2,4-thiadiazole aldehydes, 6 and 9, respectively, the synthetic routes shown in Scheme 2a were employed. First, the reaction of benzothioamide with N,N-dimethylalkanamide dimethyl acetals produced the corresponding N′-(thioaroyl)-N,Ndimethylamidines 1 and 2 in excellent yield. 20 These intermediates were converted by amination-cyclization into the 1,2,4-thiadiazole 3 and 4. The 3-formyl-1,2,4-thiadiazole 6 was obtained through bromination-oxidation of thiadiazole 4.
Attempts to obtain aldehyde 6 using formylation reaction between 5-phenyl-1,2,4-thiadiazole 3 and n-BuLi in DMF were unsuccessful. In these conditions, the ring-opening product, 5, was mainly generated. Oxidation of the methyl substituent in compound 4 using selenium dioxide was also explored in the preparation of aldehyde 6; however, no reaction was observed. Second, nitrile sulfide, obtained in situ through thermolysis of the 1,3,4-oxathiazol-2-one 7 (Scheme 2a), was treated with ethyl cyanoformate, yielding ester 8 via a 1,3-dipolar cycloaddition process. 21 Subsequently, the desired aldehyde 9 was prepared by reduction of 8 with DIBAL-H and subsequent oxidation with MnO 2 . In order to know the 1,2,4-thiadiazole-substituents stereoelectronic/antioxidant effects (Scheme 1), different 3-aryl substitutions were studied (Scheme 2b). Consequently, aldehydes 18, 20, and 21 were prepared following the same synthetic 
Scheme 1. Heteroarylnitrones Designed as Potential Drugs for Neurodegenerative Diseases
route for aldehyde 9 preparation. Attempts to obtain the desired 4-NO 2 analogue 19 were unsuccessful because of the low stability of ester 15 in the reduction conditions (i) (Scheme 2b). The 1,2,3-thiadiazole carbonylic reagents were prepared from ethyl acetoacetate following a condensation with methyl carbazate, forming the corresponding acylhydrazone, and subsequent cyclization via Hurd-Mori reaction in the presence of thionyl chloride (Scheme 2c). 22 Then thiadiazole 22 was transformed into the key aldehydes 24 and 25 by reduction/ oxidation for the first case and by benzylic-like bromination/ oxidation for the second. Finally, the synthetic procedures for furoxan and benzofuroxan systems included, for the first heterocycle, addition to alkenes followed by intramolecular cyclization and thermointramolecular cyclization for the second one (Scheme 2d). Consequently, the reaction of cinnamyl alcohol or crotonaldehyde with NaNO 2 in AcOH produced the furoxan derivatives 26 and 28, respectively. 23 Alcohol 26 was converted into the aldehyde 27 by oxidation with MnO 2 . 23 The formylbenzofuroxan 29 was obtained from 4-chloro-3-nitrobenzaldehyde in a one-pot process via nucleophilic substitution with the azide anion and subsequent cyclization by pyrolysis of the corresponding o-nitrophenylazide intermediate. 24 The desired nitrones, 30-41, were obtained in good yield for reaction between the corresponding aldehydes 6, 9, 18, 20, 21, 24, 25, 27-29 and N-substituted hydroxylamine hydrochloride in the presence of NaHCO 3 (Scheme 3). Taking into account that the nitrone stability, as well as the stability of the corresponding spin-adduct (nitroxyl free radical), is highly influenced by the N-alkyl substituent, 13 we developed derivatives 31-33 by varying R 1 (Scheme 3) in order to evaluate the effect of this modulation in the bioactivity studies.
All the structures of the desired nitrones, 30-41, were established by NMR ( 1 H, 13 C, HMQC, and HMBC experiments), IR, and MS. The purity was established by TLC and microanalysis. The stereochemistry around the olefinic carbonnitrogen bond of the nitrone function was established using NOE-diff experiments, and they are Z-isomers in all the cases.
Biology. Neuroprotective Activity. The neuroprotective activity of the new developed heteroarylnitrones, 30-41, was studied using a human neuronal-like cellular system (SH-SY5Y cells) exposed to H 2 O 2 as oxidative damaging agent. 25 First, SH-SY5Y cytotoxicity of the developed heteroarylnitrones and PBN was evaluated in vitro in the range 0.05-10 µM for 24 h. The cell viability was determined by measuring the activity of lactate dehydrogenase (LDH) released into the culture medium and expressed as the difference between nitrones-treated and untreated cells. All the nitrones displayed no cytotoxicity for neuronal cells, 100% of survival, at assayed neuroprotective doses (10 µM). Second, each one of the heteroarylnitrones, at 10 µM doses, was administered to the cells 1 h before the incubation with H 2 O 2 . The cell viability was determined by measuring the activity of LDH released and expressed as the difference between nitrones-treated and untreated cells. The basal percentage of viable neurons after treatment with 100 µM H 2 O 2 was 45%, and N-acetylcysteine (NAC) was used as positive test at 5 mM (Figure 3) . The values summarized in Table 1 show that the 1,2,4-thiadiazolylnitrones 30-36 and the furoxanylnitrone 40 protect similarly to or slightly higher against the cellular damage than the parent nitrone PBN, with values between 33% and 46%. Interestingly, the treatment of SH-SY5Y cells with the 1,2,4-thiadiazolylnitrone 36 at 1 µM significantly protects against H 2 O 2 induced neurotoxicity, with a value of 20% (Figure 3) . Furthermore, the benzofuroxanylnitrone 41 showed lower capacity to protect neuroblastoma human cells from death induced by oxidative stress than PBN, while the 1,2,3-thiadiazolylnitrones (37 and 38) and furoxanylnitrone 39 did not show neuroprotective effects. These results revealed the consequence of the connectivity and the nature of the nitronepharmacophore substituents in the neuroprotective activity. The 1,2,4-thiadiazolylnitrones 31, 32, and 33, substituted in the nitrogen atom of the nitrone by a tert-butyl, cyclohexyl, and benzyl group, respectively, exhibited differential activity, indicating some N-alkyl moieties dependence. Mammal Cytotoxicity. Unspecific mammalian cytotoxicity of the developed heteroarylnitrones was evaluated in vitro in the range 50-400 µM, using J774 mouse macrophages as the cellular model (Table 1) . 26 In the study PBN was included as a neuroprotective reference compound. The developed heteroarylnitrones displayed no cytotoxicity for mammalian cells at its neuroprotective doses (10 µM). Furthermore, the most active heteroarylnitrones, 35, 36 and 40, show low mammalian cytotoxicity in the assayed in vitro model, these compounds being as cytotoxic as the parent compound PBN. Moreover, the IC 50 values summarized in Table 1 show that the 1,2,4-thiadiazolyl, 32-34, furoxanyl, 39, and benzofuroxanylnitrones, 41, are a little more toxic against this cellular system than the parent compound PBN.
Blood-Brain Barrier Permeation Studies. For the 1,2,4-thiadiazolylnitrones 35 and 36, with the best neuroprotective profile and the lowest mammalian cytotoxicity (Table 1) , the capacity to cross the blood-brain barrier (BBB) by means of a parallel artificial membrane permeation assay for BBB (PAMPA-BBB) using a lipid extract of porcine brain was determined. The assay validation was made by comparing experimental permeabilities of 20 commercial drugs to reported values. 27 From this experiment and taking into account the limit established by Di et al. for BBB permeation, compounds with permeability (P e ) above 4.4 × 10 -6 cm s -1 could cross the BBB ( Figure 4 ).
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Free-Radical Scavenger Properties Antioxidant Activity. The antioxidant activity of the newly developed heteroarylnitrones was determined using two in vitro assays, the oxygen radical absorbance capacity (ORAC) and the measurement of reduction percentage (RP) of the stable diphenylpicrylhydrazyl free radical (DPPH). ORAC assay 29 measures peroxyl free radical scavenger compounds capability and using fluorescein (FL) as the fluorescent probe. The peroxidation of FL yields nonfluorescent products at 520 nm, so the remaining fluorescence of FL in the presence of the free radical scavenger compound is a measure of the antioxidant activity of the test compound. In this assay the results were expressed in reference to PBN, as PBN equiv (µmoles of PBN equivalents per µmoles of tested compound) ( Table 2 ). On the other hand, the RP of DPPH is based on the reaction between the deep-violet stable free radical (characterized by an absorption band in ethanol solution centered at 520 nm) and the studied free radical scavenger measuring the absorbance of nitrone-treated and untreated DPPH solutions (Table 2) . 30 The peroxyl free radical scavenger property of our nitrones, according to ORAC assay, was better than that of PBN, being 1.5-16.5 higher than PBN value. The benzofuroxanylnitrone 41 showed the highest ORAC FL value (16.5 PBN equiv), whereas the 1,2,4-thiadiazolylnitrone 34 showed the lowest ORAC FL value (1.5 PBN equiv). Similar results of antioxidant OHspin trapping ability of the developed heteroarylnitrones was investigated using ESR spectroscopy. The • OH free radical was generated in situ from a Fenton reaction system. All the assayed heteroarylnitrones, except the thiadiazolylnitrones 32 and 33 and furoxanylnitrone 39, gave strong ESR signals ( Figure 5 ), and the hyperfine splitting (HFS) constants for the different spin adducts are reported in Table 3 . These data indicate that in general our heteroarylnitrones generate stable spin adducts with • OH, like previously reported imidazolylnitrones. 31 The absence of signal in the cases of nitrones 32 and 33 indicated that the cyclohexyl and benzyl groups affect the stability of the spin adduct generated under the studied conditions.
In order to study the capability of the developed nitrones as spin trapping against other free radical species, we selected one nitrone from each proposed family. Consequently, the 1,2,4-thiadiazolylnitrone 31, the 1,2,3-thiadiazolylnitrone 38, and the furoxanylnitrone 40 were studied as both ethanol and sulfite free radical spin trappings. The ESR signals obtained for these heteroarylnitrones are given in Figure 5 . The ESR signals for the free radical adducts with nitrones 31, 38, and 40 indicated that these nitrones are also very efficient to trap and stabilize both carbon-and sulfur-centered free radicals, CH 3
• CHOH and SO 3
•-, respectively. These results suggest that our nitrones have great capacity to scavenge free radicals and potential use to prevent or reduce the damage caused by radicals in several degenerative disorders. However, because nitrone 38 is very efficient in spin trapping (i.e.,
• OH, CH 3 • CHOH, SO 3
•-, Figure  5 ), it does not have neuroprotective effects in the neuroblastoma • CH2OH, and SO3
•-free radicals with nitrones 31, 38, and 40. Superscript "a" in the heading entries indicates that
• OH, CH3
• CHOH, and SO3
•-free radicals are generated by Fenton's reaction. human SH-SY5Y system ( Table 1 
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Conclusion
New series of thiadiazolyl and furoxanylnitrones have been synthesized and biologically evaluated as potential neuroprotective agents for the treatment of neurodegenerative disorders. The designed heteroarylnitrones were efficiently obtained through the condensation between heteroaromatic aldehydes and N-monosubstituted hydroxylamines with good to excellent yields and chromatographically isolated as pure Z-isomers. They show excellent free radical scavenger capacity and good neuroprotective effects without cellular toxicity. The ESR spectroscopy demonstrated the ability of these heteroarylnitrones to directly scavenge different free radicals (i.e.,
• OH, CH 3 • CHOH, SO 3 •-). Taking into account all the results, the designed heteroarylnitrones have demonstrated a therapeutic potential as neuroprotective agents in preventing the death of cells exposed to enhanced oxidative stress and damage. Further structural optimization, QSAR, and in vivo neuroprotective property studies are currently underway. 23 were prepared according to literature procedures. Melting points were determined with an electrothermal melting point apparatus (Electrothermal 9100) and are uncorrected. Proton and carbon NMR spectra were recorded on a Bruker DPX-400 spectrometer. The chemical shifts values are expressed in ppm relative to tetramethylsilane as internal standard. Mass spectra were determined in a MSD 5973 HewlettPackard or LC/MSD series 100 Hewlett-Packard spectrometer using electronic impact (EI) or electrospray ionization (ESI), respectively. Microanalyses were performed in a Fisons EA 1108 CHNS-O equipment and were within (0.4% of the calculated compositions. Column chromatography was carried out using Merck silica gel (60-230 mesh). Most chemicals and solvents were analytical grade and used without further purification. All the reactions were carried out in a nitrogen atmosphere. The typical workup included washing with brine and drying the organic layer with sodium sulfate before concentration.
Experimental Section
3-Formyl-5-phenyl-1,2,4-thiadiazole (6). A mixture of 4 20 (0.4 g, 2.3 mmol), N-bromosuccinimide (0.45 g, 2.5 mmol), and dibenzoyl peroxide (0.08 g, 0.34 mmol) in dry CCl 4 (8.0 mL) was heated at reflux for 16 h. Then the mixture was allowed to cool to room temperature, the succinimide was collected and washed with CCl 4 (10.0 mL), and the organic layer was evaporated in vacuo. 3-Bromomethyl-5-phenyl-1,2,4-thiadiazole was obtained as an oil (∼40% by 1 H NMR signals) and was used in the next reaction without further purification.
1 H NMR (CDCl 3 , 400 MHz) δ: 4.69 (s, 2H), 7.45-7.55 (m, 3H), 7.90-8.00 (m, 2H). The crude of the bromination process in DMSO (6.0 mL) was stirred and warmed at 105°C during 1.5 h. Subsequently, the mixture was poured into saturated sodium chloride solution (30.0 mL) and extracted with EtOAc (3 × 20.0 mL). After the workup of the combined organic layers, the residue was purified by column chromatography (SiO 2 , petroleum ether/EtOAc (9:1)), yielding derivative 6 as a yellow oil (130 mg, 30% two steps). 9 and 18-21) . A solution of the corresponding ester 20, [33] [34] [35] [36] (1 equiv) in THF (4 mL/mmol) as solvent was cooled at 0°C. Then a solution of DIBAL-H (1 M in hexane, 2-3 equiv) was added slowly and the final mixture was stirred during 3 h. The reaction mixture is diluted with EtOAc and washed with HCl (1 M). After the workup, the residue, corresponding to the 3-aryl-5-hydroxymethyl-1,2,4-thiadiazole (pure by TLC), was used in the next reaction without further purification. Subsequently, a mixture of the corresponding alcohol (1 equiv) and MnO 2 (10 equiv) in CHCl 3 (12 mL/mmol) as solvent was heated at reflux until absence of the alcohol (checked by TLC). The resulting dispersion was then filtered through a short pad of Celite, the organic phase concentrated in vacuo and the residue purified by column chromatography (SiO 2 , petroleum ether/EtOAc (8:2)) to afford spectroscopically pure compounds. 
5-Ethoxycarbonyl-4-methyl-1,2,3-thiadiazole (22).
A mixture of ethyl acetoacetate (4.9 mL, 38.5 mmol), methyl carbazate (3.8 g, 42.4 mmol), and p-TsOH (catalytic amounts) in toluene (120.0 mL) was heated at reflux for 2 h. Then the solvent was concentrated in vacuo and the crude of the reaction was used in the next reaction without further purification. The acylhydrazone obtained was cooled at 0°C, and SOCl 2 (20.0 mL, 270 mmol) was added dropwise with stirred during 10 min. The final mixture was stirred during 2 h at 60°C, the excess of SOCl 2 was evaporated in vacuo, and the residue was neutralized with aqueous saturated NaHCO 3 and extracted with EtOAc (3 × 10 mL). After the workup the organic solvent was evaporated in vacuo and the crude purified by column chromatography (SiO 2 , petroleum ether/EtOAc (8:2)), yellow oil, 1.63 g (25%). 1 
5-Hydroxymethyl-4-methyl-1,2,3-thiadiazole (23).
A solution of 22 (0.8 g, 4.7 mmol) in EtOH (8.0 mL) was cooled at 0°C. Then NaBH 4 (0.3 g, 7.9 mmol) was added slowly and the final mixture was stirred during 2 h at room temperature. The organic solvent was evaporated in vacuo, and the residue was treated with H 2 O (50.0 mL) and extracted with EtOAc (3 × 10.0 mL). After the workup the organic solvent was evaporated in vacuo. The residue was purified by column chromatography (SiO 2 , petroleum ether/ EtOAc (7:3)), yielding derivative 23 as a yellow oil (0.42 g, 70%) . 1 -4-formyl-1,2,3-thiadiazole (25) . A mixture of 22 (1.0 g, 5.8 mmol), N-bromosuccinimide (1.14 g, 6.4 mmol), and dibenzoyl peroxide (0.06 g, 0.23 mmol) in dry CCl 4 (40.0 mL) was heated at reflux for 16 h. Then the mixture was allowed to cool to room temperature, the succinimide was collected and washed with CCl 4 , and the organic layer was evaporated in vacuo. DMSO (10.0 mL) was added, and the mixture was warmed at 120°C during 3 h. Then EtOAc (50 mL) was added and the organic layer was washed with saturated sodium chloride solution (40.0 mL). After the workup the organic solvent was evaporated in vacuo and the residue purified by column chromatography (SiO 2 , petroleum ether/ EtOAc (8:2)), yielding a yellow oil that crystallized at 4°C (0.4 g, 40% (Z)-(3-Phenyl-1,2,4-thiadiazol-5-yl)-N-benzylnitrone (33 45 (m, 3H), 7.48 (s, 5H), 8.30-8.27 (m, 2H), 8.35  (s, 1H) . 13 Measurement of Cell Viability. Culture of SH-SY5Y Cells. SH-SY5Y cells, at passages between 3 and 16 after defreezing, were maintained in a minimum essential medium (MEM) containing 15 nonessential amino acids (NEAAs) and supplemented with 10% fetal bovine serum, 1 mM glutamine, 50 units/mL penicillin, and 50 µg/mL streptomycin (reagents from GIBCO, Madrid, Spain). Cultures were seeded into flasks containing supplemented medium and maintained at 37°C in 5% CO 2 /humidified air.
Cell Viability Assays. The effects of nitrones on SH-SY5Y cell viability were determined by measuring the activity of LDH released into the culture medium (Cytotox 96 LDH assay, Promega, U.K.). The assay was performed in accordance with the manufacturer's protocol using SH-SY5Y cells seeded at 10 4 cells/well in 96-well plates. Cells were exposed to 10, 1, and 0.05 µM of each one nitrone for 24 h.
The effects of H 2 O 2 on SH-SY5Y cell viability were determined by measuring the activity of LDH released into the culture medium (Cytotox 96 LDH assay, Promega, U.K.). The assay was performed in accordance with the manufacturer's protocol using SH-SY5Y cells seeded at 10 4 cells/well in 96-well plates. Cells were exposed to 10 µM of each one heteroarylnitrone for 1 h and subsequently exposed to 100 µM H 2 O 2 for 24 h. An amount of 5 mM NAC was used as positive test.
Unspecific Mammalian Cytotoxicity. J774 murine macrophagelike cells (ATCC) were maintained by passage in Dulbecco's modified Eagle's medium (DMEM) containing 4 mM L-glutamine and supplemented with 10% heat-inactivated fetal calf serum. J774 cells were seeded (1 × 10 5 cells/well) in 96-well microplates with 100 µL of RPMI medium supplemented with fetal serum. Cells were allowed to attach for 48 h in a humidified 5% CO 2 /95% air atmosphere at 37°C and then exposed to nitrones (50-500 µM) for 48 h. Afterward, cell viability was assessed by measuring the mitochondrial-dependent reduction of 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide (MTT, Sigma) to formazan. For that purpose, MTT was added to cells to a final concentration of 0.2 mg/mL and cells were incubated at 37°C for 3 h. After removal of the media, formazan crystals were dissolved in DMSO, and the absorbance at 560 nm was read using a microplate spectrophotometer. Results are expressed as IC 50 (compound concentration that reduce 50% control absorbance at 560nm). Every IC 50 is the average of two different experiments.
Blood-Brain Barrier Permeation Assay. Brain penetration of new nitrones was evaluated using a parallel artificial membrane permeation assay (PAMPA) in a similar manner as described previously. 27 Commercial drugs were purchased from Sigma, Aldrich, Acros, and Fluka. Millex filter units (PVDF membrane, diameter 25 mm, pore size 0.45 µm) were acquired from Millipore. The porcine brain lipid (PBL) was obtained from Avanti Polar Lipids. The donor microplate was a 96-well filter plate (PVDF membrane, pore size 0.45 µm), and the acceptor microplate was an indented 96-well plate, both from Millipore. The acceptor 96-well microplate was filled with 170 µL of PBS/ethanol (9:1), and the filter surface of the donor microplate was impregnated with 4 µL of PBL in dodecane (20 mg/mL). Compounds were dissolved in PBS/ethanol (9:1) at 1 mg/mL, filtered through a Millex filter, and then added to the donor wells (170 µL). The donor filter plate was carefully put on the acceptor plate to form a sandwich, which was left undisturbed for 120 min at 25°C. After incubation, the donor plate was carefully removed and the concentration of compounds in the acceptor wells was determined by UV spectroscopy. Every sample was analyzed in four wells and at least in three independent runs, and the results are given as the mean ( standard deviation.
Determination of Antioxidant Activity. OFRAC FL Assay. A luminescence spectrometer LS 50B (PerkinElmer, Boston, MA), a heating circulator bath DC1-B3 (Haake Haake Fisons, Karlsruhe, Germany), and quartz cuvettes were used. For the ORAC FL assay, the 490-P excitation and 515-P emission filters were used, and the fluorescence measurement was carried out at 60°C. The method of Ou et al. 29 was modified as follows: the reaction was carried out in 75 mM phosphate buffer (pH 7.4), and the final reaction volume was 3000 µL. Studied compounds (10-1000 µM final concentrations) and fluorescein (215 µL, 70 nM final concentration) solutions were placed in the quartz cuvette. The mixture was preincubated for 30 s at 60°C. 2,2′-Azobis(2-amidinopropane) dihydrochloride (AAPH) solution (240 µL; 12 mM, final concentration) was added rapidly using a single channel pipet. The quartz cuvette was immediately placed in the luminescence spectrometer and the fluorescence recorded every minute for 12 min. As a blank FL + AAPH in phosphate buffer instead of the studied compounds solutions were employed, and eight calibration solutions using Trolox (1-8 µM, final concentration) as antioxidant positive control were also carried out in each assay. All the reaction mixtures were prepared in duplicate, and at least three independent assays were performed for each sample. Raw data were exported to an OriginPro (OriginLab Corporation, Northampton, MA) sheet for further calculations. Blank and antioxidant curves (fluorescence versus time) were first normalized by dividing original data by fluorescence at t ) 0 s. From the normalized curves, the area under the fluorescence decay curve (AUC) was calculated as
where f 0 is the initial fluorescence reading at 0 min and f i is the fluorescence reading at time i. The net AUC corresponding to each sample was calculated by subtracting the AUC corresponding to the blank. Regression equations between net AUC and antioxidant concentration were calculated for all the samples. ORAC FL values were expressed as PBN equivalents by using the standard curve calculated for each assay. Final results were expressed in µmole of PBN equivalent per µmole of samples.
DPPH Assay. The reaction was carried out in 96-well microplates, and the final reaction mixture was 100 µL per well. Antioxidant (0.1 mM, final concentration) and DPPH (0.1 mM, final concentration) were dissolved in EtOH and preincubated for 5 min at 37°C, and the absorbance at 520 nm was read using a microplate spectrophotometer. The antioxidant activity was determined as the RP of DPPH, calculated as follows: RP ) 100 [(A 0 -A c )/A 0 ], where A 0 is the untreated DPPH absorbance and A c is the value for added sample concentration c.
ESR Spectroscopy. The spin trapping ability of the developed heteroarylnitrones was studied by ESR spectroscopy. ESR spectra were recorded in the X band (9.85 GHz) using a Bruker ECS 106 spectrometer with a rectangular cavity and 50 kHz field modulation. All the spectra were registered in the same scale after 15 scans. The hyperfine splitting constants were estimated to be accurate within 0.05 G.
Generation of Free Radicals. Hydroxyl radical (
• OH) was generated from a standard Fenton system: Fe(NH 4 ) 2 (SO 4 ) 2 · 6H 2 O (50 µL, 0.5 mM) was added to a solution of nitrone (50 mM, final concentration) and H 2 O 2 (50 µL, 0.5 mM) in phosphate buffer (final reaction mixture was 250 µL). Cysteinyl radical (SO 3
•-) was generated from a standard Fenton system: Fe(NH 4 ) 2 (SO 4 ) 2 · 6H 2 O (50 µL, 0.5 mM) was added to a solution of nitrone (50 mM, final concentration), Na 2 SO 3 (50 µL, 250 mM), and H 2 O 2 (50 µL, 0.5 mM) in phosphate buffer (final reaction mixture was 250 µL).
Ethanol radical (CH 3
• CHOH) was generated from a standard Fenton system: Fe(NH 4 ) 2 (SO 4 ) 2 · 6H 2 O (50 µL, 0.5 mM) was added to a solution of nitrone (50 mM, final concentration), EtOH (50 µL), and H 2 O 2 (50 µL, 0.5 mM) in phosphate buffer (final reaction mixture was 250 µL).
